Stock ACTI ACTIVE BIOTECH AB
Add to a list
To use this feature you must be a member
Log inSign up

Active Biotech AB Stock

Equities

ACTI

SE0001137985

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-12-13 EST 		5-day change 1st Jan Change
0.1264 SEK +5.69% Intraday chart for Active Biotech AB +0.64% -72.31%
11-19 Redeye lowers motivated value for Active Biotech to SEK 0.40 (0.50) FW
11-19 Active Biotech's rights issue was oversubscribed, over-allotment has been utilized FW

Valuation: Active Biotech AB

Capitalization 155M 14.16M 13.49M 12.64M 11.21M 20.15M 1.2B 22.27M 57.51M 495M 53.19M 52M 2.18B P/E ratio 2024 *
-
P/E ratio 2025 * -
Enterprise value 162M 14.71M 14.01M 13.14M 11.65M 20.94M 1.25B 23.15M 59.76M 514M 55.28M 54.04M 2.26B EV / Sales 2024 *
-
EV / Sales 2025 * 16.7x
Free-Float
-
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data

Chart: Active Biotech AB

Dynamic Chart

Latest news: Active Biotech AB

Redeye lowers motivated value for Active Biotech to SEK 0.40 (0.50) 11-19 FW
Active Biotech's rights issue was oversubscribed, over-allotment has been utilized 11-19 FW
Active Biotech Raises SEK43.4 Million from Oversubscribed Rights Offering 11-19 MT
Active Biotech to receive US patent for laquinimod in eye diseases 11-13 FW
Active Biotech's preclinical data on tasquinimod presented at ASH 11-05 FW
Active Biotech Announces an Abstract with Preclinical Data for tasquinimod in myelofibrosis At ASH 2024 11-05 CI
Active Biotech Receives EU Approval for Tasquinimod Study 10-30 MT
Active Biotech's tasquinimod study receives green light from EMA 10-30 FW
Active Biotech Announces Approval of Clinical Trial of Tasquinimod in Myelofibrosis in Europe 10-30 CI
Analysis guide adjusts downwards the motivated value for Active Biotech due to new share issue 10-29 FW
Active Biotech is traded today excluding subscription rights in rights issue 10-25 FW
Redeye lowers motivated value for Active Biotech 10-23 FW
Active Biotech granted patent for laquinimod eye drop formulation 10-23 FW
More news

Analysts' recommendations: Active Biotech AB

Redeye lowers motivated value for Active Biotech to SEK 0.40 (0.50) 11-19 FW
Analysis guide adjusts downwards the motivated value for Active Biotech due to new share issue 10-29 FW
Redeye lowers motivated value for Active Biotech 10-23 FW
Analysguiden lowers motivated value for Active Biotech 05-14 FW
Analysis Guide maintains motivated value for Active Biotech 02-15 FW
More recommendations

Press Releases: Active Biotech AB

Active Biotech : Positive preclinical tasquinimod data in myelofibrosis presented at ASH 2024 now available on Active Biotech's website 12-09 PU
Positive preclinical tasquinimod data in myelofibrosis presented at ASH 2024 now available on Active Biotech’s website 12-09 AQ
Active Biotech raises SEK 43.4 million in substantially oversubscribed rights issue including exercise of over-allotment option 11-18 AQ
Active Biotech : patent for laquinimod in eye disorders will be granted in the US 11-13 PU
Active Biotech’s patent for laquinimod in eye disorders will be granted in the US 11-13 AQ
More press releases

News in other languages: Active Biotech AB

IPSEN : nouveau paiement d'étape de 12 millions d'euros à Active Biotech pour le Tasquinimod 13-10-09
IPSEN : et Active Biotech achèvent le recrutement pour l'étude phase III avec tasquinimod 12-12-10
BNP PARIBAS : INDICES : Le CAC 40 réduit sa perte à la mi-journée 12-05-18
IPSEN : résultats positifs d'une étude sur le tasquinimod 12-05-18
IPSEN : les données de tolérance de tasquinimod présentées du 24 au 28 février 12-02-24
More news

Quotes and Performance

1 day+5.69%
1 week+0.64%
Current month-53.01%
1 month-56.56%
3 months-68.12%
6 months-75.36%
Current year-72.31%
More quotes

Course Extremes

1 week
0.11
Extreme 0.105
0.14
1 month
0.11
Extreme 0.105
0.44
Current year
0.11
Extreme 0.105
1.48
1 year
0.11
Extreme 0.105
1.48
3 years
0.11
Extreme 0.105
1.52
5 years
0.11
Extreme 0.105
4.31
10 years
0.11
Extreme 0.105
31.60
More quotes

Managers and Directors: Active Biotech AB

Director TitleAgeSince
Helén Tuvesson CEO
 Chief Executive Officer 62 2017-06-30
Hans Kolam DFI
 Director of Finance/CFO 73 1999-12-31
Erik Vahtola CTO
 Chief Tech/Sci/R&D Officer - 2021-12-31
Manager TitleAgeSince
Karl Peter Thelin BRD
 Director/Board Member 68 2011-04-06
Michael Shalmi CHM
 Chairman 59 2019-05-22
Uli Alf Hacksell BRD
 Director/Board Member 74 2019-05-22
More insiders

Bio Therapeutic Drugs

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
ACTIVE BIOTECH AB Stock Active Biotech AB
+5.69%+0.64%-72.64%-90.57%14.16M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-0.08%+0.35%+14.48%+122.79%119B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
-1.31%-6.00%-16.53%+10.78%78.68B
ARGENX SE Stock argenx SE
-0.14%-1.69%+36.31%+117.61%36.8B
BIONTECH SE Stock BioNTech SE
-0.26%-1.10%+23.87%-56.73%28.86B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-1.03%+2.32%-23.68%-58.23%22.22B
BEIGENE, LTD. Stock BeiGene, Ltd.
-0.51%-12.78%-2.17%-36.61%19.06B
SUMMIT THERAPEUTICS INC. Stock Summit Therapeutics Inc.
-0.22%-3.83%+661.97%+277.75%13.15B
GENMAB A/S Stock Genmab A/S
-3.33%-7.13%-32.87%-42.44%12.86B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
-0.07%-1.12%+2.55%+53.74%12.83B
Average -0.03%-3.44%+59.13%+29.81% 34.39B
Weighted average by Cap. -0.56%-2.39%+29.66%+58.18%
See all sector performances

Financials

2024 *2025 *
Net sales - 9.3M 847K 807K 756K 671K 1.21M 71.81M 1.33M 3.44M 29.59M 3.18M 3.11M 130M
Net income -38.8M -3.53M -3.37M -3.16M -2.8M -5.03M -300M -5.56M -14.35M -123M -13.27M -12.97M -543M -26.8M -2.44M -2.32M -2.18M -1.93M -3.47M -207M -3.84M -9.91M -85.27M -9.17M -8.96M -375M
Net Debt 6.1M 555K 529K 496K 440K 791K 47.1M 874K 2.26M 19.41M 2.09M 2.04M 85.33M -
More financial data * Estimated data

Company Profile

Logo Active Biotech AB
Active Biotech AB (publ) is a Sweden-based Company, which develops pharmaceutical products within medical areas where the immune defense is important, including cancer and inflammatory diseases. The project portfolio comprises both small, orally active immunomodulatory molecules and antibody-based immunotherapy.
Employees
6
Sector
Biotechnology & Medical Research
Calendar
2025-02-13 - Q4 2024 Earnings Release
More about the company

Quotes

Date Price Change Volume
24-12-13 0.1264 kr +5.69% 41,217,890
24-12-12 0.1196 kr +4.73% 6,548,398
24-12-11 0.1142 kr +0.53% 8,643,245
24-12-10 0.1136 kr -9.70% 16,444,190
24-12-09 0.1258 kr +0.16% 18,395,190

Delayed Quote Nasdaq Stockholm, December 13, 2024 at 12:00 pm

More quotes

Income Statement and Estimates

income-statement-evolution-chart ACTIVE-BIOTECH-AB More financial data

Net sales - Rate of surprise

quality-estimates-chart ACTIVE-BIOTECH-AB Company calendar
  1. Stock Market
  2. Equities
  3. ACTI Stock
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition